Zolunicant
Zolunicant (MM-110) is a potent inhibitor against nicotinic α3β4 receptors with an IC50 of 0.90 μM to combat addiction. Zolunicant can decrease the self-administration of several addictive agents including morphine, methamphetamine, nicotine, and ethanol in rat model. Zolunicant can be studied as a potential research for multiple forms of agent abuse[1]. Zolunicant also reveals a potent leishmanicide effect against Leishmania amazonensis[2].
Product Specifications
CAS Number
188125-42-0
Product Name Alternative
MM-110; (±) -18-Methoxycoronaridine
UNSPSC
12352005
Target
NAChR; Parasite
Type
Reference compound
Related Pathways
Anti-infection; Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Infection; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/zolunicant.html
Purity
99.29
Solubility
10 mM in DMSO
Smiles
COC([C@]12[C@@]3([H])[N@@](CCC4=C2NC5=CC=CC=C54)C[C@@](C[C@@H]3CCOC)([H])C1)=O
Molecular Formula
C22H28N2O3
Molecular Weight
368.47
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Leishmania
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Magic™ Membrane Protein Human SFT2D2 (SFT2 domain containing 2) Expressed in vitro E.coli expression system, Full Length
Recombinant Human respiratory syncytial virus A Major surface glycoprotein G (G), partial, Biotinylated
Recombinant Human respiratory syncytial virus A Major surface glycoprotein G (G), partial, Biotinylated
Recombinant Human respiratory syncytial virus A Major surface glycoprotein G (G), partial, Biotinylated